Description
While the study identifies adenine nucleotide translocase dysregulation as a key mechanism in VCP-related mitochondrial dysfunction, it remains unknown whether targeting this translocase therapeutically could prevent or reverse neurodegeneration. This represents a critical translational gap for developing treatments.
Gap type: open_question Source paper: Mutations in valosin-containing protein (VCP) decrease ADP/ATP translocation across the mitochondrial membrane and impair energy metabolism in human neurons. (2017, The Journal of biological chemistry, PMID:28360103)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:48.191742+00:00”, “resolution_summary”: “Resolved by hypothesis SDA-2026-04-02-gap-tau-prop-20260402003221-H004: VCP-Mediated Autophagy Enhancement. Supporting evidence includes debate sess_SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88_20260413-225852.”, “match_counts”: {“hypothesis_matches”: 3, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “SDA-2026-04-02-gap-tau-prop-20260402003221-H004”, “title”: “VCP-Mediated Autophagy Enhancement”, “score”: 0.359, “reason”: “22 token overlaps; entity overlap: vcp, vcp-”, “analysis_id”: “SDA-2026-04-04-gap-tau-prop-20260402003221”, “target_gene”: “VCP”, “target_pathway”: “VCP/p97 proteostasis / autophagy”, “disease”: “neurodegeneration”, “composite_score”: 0.787, “confidence_score”: 0.525, “status”: “proposed”, “pubmed_evidence_ids”: [“32048886”, “34057020”, “35678504”, “38762759”, “41324484”]}, {“id”: “h-f7da6372”, “title”: “Mitochondrial ATP/ADP Carrier Activity as Bioenergetic Recovery Metric”, “score”: 0.342, “reason”: “18 token overlaps; entity overlap: adp, atp”, “analysis_id”: “SDA-2026-04-04-gap-debate-20260403-222618-c698b06a”, “target_gene”: “SLC25A4”, “target_pathway”: null, “disease”: “translational neuroscience”, “composite_score”: 0.642, “confidence_score”: 0.4, “status”: “proposed”, “pubmed_evidence_ids”: [“40864415”, “41469700”, “41835065”]}, {“id”: “h-810ec0eb”, “title”: “TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis”, “score”: 0.24, “reason”: “26 token overlaps; entity overlap: vcp-”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88”, “target_gene”: “TFEB, MTOR”, “target_pathway”: “CLEAR network; mTORC1 signaling; calcineurin-mediated dephosphorylation; VCP-dependent autophagy”, “disease”: “neurodegeneration”, “composite_score”: 0.779, “confidence_score”: 0.52, “status”: “promoted”, “pubmed_evidence_ids”: [“19460733”, “20104022”, “21674719”, “23238394”, “25728669”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88_20260413-225852”, “title”: “The study shows VCP-mutant astrocytes exhibit hypoxia response activation without actual hypoxia, but the mechanistic link between VCP dysfunction and HIF-1α stabilization remains unexplained. Understanding this connection is critical for developing targeted therapies that could prevent early pathogenic events in VCP-ALS.\n\nGap type: unexplained_observation\nSource paper: Hypoxic stress is an early pathogenic event in human VCP-mutant ALS astrocytes. (2026, Stem cell reports, PMID:41349534)”, “score”: 0.636, “reason”: “12 token overlaps; entity overlap: pmid, vcp, vcp-”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88”, “quality_score”: 0.78, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e”, “title”: “While RGS6 deficiency causes Parkinson’s-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.\n\nGap type: open_question\nSource paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)”, “score”: 0.397, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e”, “title”: “While RGS6 deficiency causes Parkinson’s-like pathology, whether enhancing RGS6 function or targeting the D2R-Gi/o pathway can reverse or prevent established neurodegeneration remains untested. This is crucial for therapeutic development.\n\nGap type: open_question\nSource paper: Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. (2019, JCI Insight, PMID:31120439)”, “score”: 0.397, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.384, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-193244-89904941_20260416-035819”, “title”: “The abstract identifies APOE4’s primary effect on oligodendrocyte cholesterol metabolism but doesn’t explain the mechanistic pathway. Understanding this mechanism is critical for developing targeted therapeutics that address the root cause rather than downstream effects.\n\nGap type: unexplained_observation\nSource paper: APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes (2022, Nature, PMID:34788101)”, “score”: 0.384, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-193244-89904941”, “quality_score”: 0.69, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}